olivLaw · US equity research
FocalTherics™ (formerly EDAP TMS S.A.) FOCL
Electromedical & Electrotherapeutic Apparatus · SIC 3845 · Vertical: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
FocalTherics (formerly EDAP TMS, Nasdaq: FOCL) develops and sells robotic focal therapy devices based on high-intensity focused ultrasound (HIFU), with its flagship Focal One system. The company has refocused exclusively on HIFU, and HIFU division revenue rose 44.8% in fiscal 2025, making the transition relevant for investors and patients.
At the close of 04 Nov 2026, FocalTherics™ (formerly EDAP TMS S.A.) (FOCL) stock was 4.34 USD (+5.60% on the day), with beta 0.76, 52-week range 1.99–6.34 USD. Latest reported quarter (Q2 2026): revenue of 13.2 m USD (+38.8% YoY), net income of -14.5 m USD, diluted EPS -0.39 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.0
- neutral
- Bollinger (20, 2)
- 4.00 – 4.38
- in the upper half of the band · %B 0.90 · band width 9.1%
- SMA 50 / 200
- 4.25 / 4.41
- mixed trend
- MACD (12, 26, 9)
- -0.02 / -0.04
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +2.6% | −1.1% | +3.7 pp | — |
| 3 months | −28.7% | −0.5% | −28.3 pp | — |
| 6 months | +20.6% | +4.4% | +16.2 pp | — |
| Year to date | +31.9% | +12.3% | +19.6 pp | — |
| 1 year | +113.8% | +13.5% | +100.3 pp | −0.4% |
| 3 years | −38.9% | +76.4% | −115.3 pp | −29.1% |
| 5 years | −23.9% | +63.7% | −87.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · EUR
| Fiscal year | Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|
| Revenue | 14.3 m | 9.5 m | 17.8 m | 13.2 m |
| Cost of revenue | 8.3 m | 4.6 m | 9.7 m | 5.9 m |
| Gross profit | 6.0 m | 4.9 m | 8.1 m | 7.3 m |
| Research & development | 2.6 m | 2.3 m | 2.6 m | 2.3 m |
| Operating income | -6.3 m | -6.6 m | -7.4 m | -8.0 m |
| Depreciation & amortisation | 753.0 k | 846.0 k ≈ | 896.0 k | 1.0 m ≈ |
| Pre-tax income | -7.3 m | -6.3 m | -8.9 m | -14.4 m |
| Income tax | 144.0 k | 14.0 k | 145.0 k | 8.0 k |
| Net income | -7.4 m | -6.4 m | -9.1 m | -14.5 m |
| Diluted EPS | -0.20 | -0.17 | -0.24 | -0.39 |
| Operating cash flow | -5.3 m | -4.7 m ≈ | -3.0 m | -3.7 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.2 m | 44.9 m | 41.6 m | 44.1 m | 55.1 m | unavailable | 69.4 m | 70.5 m |
| Revenue YoY | +9.7% | +14.5% | −7.2% | +5.8% | +25.1% | unavailable | unavailable | +1.6% |
| Net income | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -20.6 m | -29.2 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -0.55 | -0.78 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -29.7% | -41.5% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 20.5 m EUR
- Financial debt
- 20.3 m EUR
- Net debt
- -163.0 k EUR
- Equity
- 19.4 m EUR
- Total assets
- 79.0 m EUR
- Debt / equity
- 1.05x
- Current ratio
- 1.54x
- ROE
- -94.5%
- ROA
- -34.7%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 41.6 m | 44.1 m | 55.1 m | — | 69.4 m | 70.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Cost of revenue | — | — | — | — | 40.7 m | 40.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Gross profit | — | — | — | — | 28.7 m | 30.0 m | SEC (XBRL)· 25 Mar 2026verified |
| Research & development | — | — | — | — | 8.4 m | 9.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Operating income | — | — | — | — | -22.2 m | -24.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Depreciation & amortisation | 1.7 m | 1.5 m | — | — | 2.8 m | 3.4 m | SEC (XBRL)· 25 Mar 2026verified |
| EBITDA | — | — | — | — | -19.4 m ≈ | -21.3 m ≈ | SEC (XBRL)· 25 Mar 2026derived |
| Interest expense | 108.0 k | 52.0 k | 168.0 k | 232.0 k | 256.0 k | 789.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Pre-tax income | -1.2 m | — | — | — | -20.3 m | -28.8 m | SEC (XBRL)· 25 Mar 2026verified |
| Income tax | — | — | — | — | 313.0 k | 438.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Net income | — | — | — | — | -20.6 m | -29.2 m | SEC (XBRL)· 25 Mar 2026verified |
| Diluted EPS | — | — | — | — | -0.55 | -0.78 | SEC (XBRL)· 25 Mar 2026verified |
| Weighted average diluted shares | 29.1 m | 32.4 m | 34.4 m | 37.0 m | 37.3 m | 37.4 m | SEC (XBRL)· 25 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | — | — | — | 48.0 m | 31.0 m | 20.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Receivables | — | — | — | — | 19.3 m | 14.9 m | SEC (XBRL)· 14 Aug 2026verified |
| Inventories | — | — | — | — | 19.2 m | 7.8 m | SEC (XBRL)· 14 Aug 2026verified |
| Current assets | — | — | — | — | 72.6 m | 57.2 m | SEC (XBRL)· 25 Mar 2026verified |
| Property, plant & equipment, net | — | — | — | — | 7.6 m | 9.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Goodwill | — | — | — | — | 2.5 m | 757.0 k | SEC (XBRL)· 14 Aug 2026verified |
| Intangibles (excl. goodwill) | — | — | — | — | 1.1 m | 1.8 m | SEC (XBRL)· 14 Aug 2026verified |
| Total assets | — | — | — | — | 89.4 m | 79.0 m | SEC (XBRL)· 25 Mar 2026verified |
| Short-term debt | — | — | — | — | 6.5 m | 4.4 m | SEC (XBRL)· 14 Aug 2026verified |
| Long-term debt | — | — | — | — | 2.2 m | 15.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Current liabilities | — | — | — | — | 39.3 m | 37.1 m | SEC (XBRL)· 25 Mar 2026verified |
| Total liabilities | — | — | — | — | 46.9 m | 59.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Equity | — | — | — | 62.9 m † | 42.5 m † | 19.4 m † | SEC (XBRL)· 25 Mar 2026verified |
| Shares outstanding at year end | 29.2 m | 33.5 m | 36.9 m | 37.1 m | 37.4 m | — | SEC (XBRL)· 27 Mar 2025verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | -14.7 m | -16.4 m | SEC (XBRL)· 25 Mar 2026verified |
| Investing cash flow | — | — | — | — | -4.5 m | -5.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Financing cash flow | — | — | — | — | 5.0 m | 8.6 m | SEC (XBRL)· 25 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -49.1% | 45 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 8.6% | 71 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -34.7x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 1.6x | 67 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet27/100 · 2/3 factors with a value
- Growth· partial71/100 · 1/2 factors with a value
- Quality· partial45/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
EDAP TMS SA (FOCL). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 70.5 m EUR in 2025; YoY growth 1.6%; net margin -49.1%; ROE -321.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 8.6%
What contradicts it
- Interest coverage: -34.7x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Electromedical & Electrotherapeutic Apparatus (SIC 3845) · same industry (4-digit SIC) · compared with 24 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MDTMedtronic plc | 134.3 bn | 25.8 | 10.7% | 13.9% | +8.4% | −0% / +32% |
| LIVNLivaNova PLC | 5.2 bn | 31.3 | 15.5% | 13.0% | +10.7% | +48% / +110% |
| ITGRInteger Holdings Corporation | 4.3 bn | 42.5 | 6.0% | 5.7% | +8.0% | +75% / +45% |
| AXGNAxogen, Inc. | 3.1 bn | — | -10.3% | -12.0% | +20.2% | +79% / +684% |
| TMDXTransMedics Group, Inc. | 2.5 bn | 18.9 | 36.3% | 22.7% | +37.1% | −50% / −4% |
| BLFSBioLife Solutions, Inc. | 1.9 bn | 33.5 | 15.1% | 56.4% | +28.9% | unavailable / unavailable |
| CNMDConmed Corporation | 1.6 bn | 21.8 | 7.1% | 5.4% | +5.2% | +24% / −50% |
| CBLLCeriBell, Inc. | 1.1 bn | — | -52.5% | -68.0% | +36.1% | +61% / unavailable |
| INMDInMode Ltd. | 899.7 m | 9.9 | 13.5% | 25.3% | −6.2% | −0% / −40% |
| CVCapsoVision, Inc | 342.8 m | — | — | -214.7% | +15.3% | +23% / unavailable |
| ELMDElectromed, Inc. | 234.3 m | 21.5 | 23.3% | 15.3% | +15.3% | +5% / +172% |
| FOCLEdap Tms SA | 162.9 m | — | -321.7% | -49.1% | +1.6% | +114% / −39% |
| VANIVivani Medical, Inc. | 96.5 m | — | -220.4% | — | unavailable | −21% / +13% |
| STXSStereotaxis, Inc. | 95.9 m | — | -325.9% | -74.2% | +20.3% | −61% / −42% |
| NRXSNeuraxis, Inc. | 86.1 m | — | -139.8% | -144.4% | +32.9% | +147% / +117% |
| OMOutset Medical, Inc. | 83.8 m | — | -63.0% | -58.3% | +5.1% | −3% / −94% |
| ECORelectroCore, Inc. | 77.5 m | — | — | -33.5% | +27.2% | +66% / +49% |
| POCIPrecision Optics Corporation, Inc. | 53.1 m | — | -22.3% | -11.5% | +65.2% | +3% / −18% |
| NXLNexalin Technology, Inc. | 34.4 m | — | -240.3% | -4,139.4% | +78.8% | −95% / −87% |
| QTIQt Imaging Holdings, Inc. | 32.1 m | — | -2,125.0% | -77.3% | +287.9% | −64% / −99% |
| NUWENuwellis, Inc. | 19.2 m | — | — | -125.6% | −5.4% | −94% / −100% |
| IRIXIridex Corp | 12.6 m | — | -73.1% | -6.9% | unavailable | −26% / −72% |
| NDRAEndra Life Sciences Inc. | 7.4 m | — | -152.0% | — | unavailable | −16% / −100% |
| HYPRHyperfine, Inc. | 0 | — | -97.0% | -210.8% | +5.2% | −30% / −41% |
| ITOCiTonic Holdings Ltd | — | — | -82.8% | -974.7% | +16.7% | −80% / unavailable |
1- and 3-year price returns: for FOCL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
FocalTherics (formerly EDAP TMS, Nasdaq: FOCL) develops and sells robotic focal therapy devices based on high-intensity focused ultrasound (HIFU), with its flagship Focal One system. The company has refocused exclusively on HIFU, and HIFU division revenue rose 44.8% in fiscal 2025 1, making the transition relevant for investors and patients.
SWOT
Strengths
- Proprietary HIFU platform with published comparative clinical data and FDA and CE authorisations for several indications.
- Rapid growth in equipment and treatment sales, with gross margin rising in the first half of 2026 2.
- Clear strategic focus on one main product, which simplifies operations and research investment.
Weaknesses
- Recurring net losses and rising sales and marketing costs, with a large net loss in 2025 1.
- Significant debt and reliance on European Investment Bank financing, with profit effects from warrant valuation changes.
- Dependence on a single manufacturing site and a small number of suppliers.
Opportunities
- Expansion into BPH and endometriosis, with a programme already launched in Europe.
- The U.S. market, where procedure growth was reported as strong in the second quarter of 2026 3.
- Integration of histotripsy and telecollaboration into the Focal One platform, if development succeeds.
Threats
- Tariff pressure and geopolitical instability affecting costs and international sales.
- Risk that reimbursement or adoption by the medical community is slower than expected.
- Risk that new technologies make the platform obsolete or less competitive.
Risks
- Need for additional financinghigh
The company could need additional capital, and terms of new financing could be unfavourable to existing shareholders 1.
- Dependence on HIFU technologyhigh
Strategic success depends almost entirely on HIFU technology; failure to expand indications could weigh on growth 1.
- Exit from legacy segmentsmedium
Exiting ESWL and Distribution could weigh on revenue until the transactions are completed 12.
- Product liability and AI issuesmedium
Misuse of products or problems with AI could lead to legal liability or reputational harm 1.
- Volatile results and currency exposurelow
Quarterly results have fluctuated significantly and currency exposure could affect margins 1.
Investment thesis
What would need to be true (bull case)
- If growth in HIFU revenue and gross margin holds, the company could gradually reduce operating losses.
- Comparative clinical data and authorisations for several indications could support broader adoption of the Focal One platform.
- Exiting legacy activities could focus resources on the higher-margin segment.
What would break the thesis
- Net losses and the need for additional financing could limit the company's ability to invest in growth.
- Dependence on one product and one manufacturing site could leave the company exposed to disruption.
- Slow physician adoption or limited reimbursement could delay reaching growth targets.
What to watch
- Revenue guidance for 2026 and delivery in coming quartersQ3 2026
- Completion of the 40 million USD public offering and use of proceedsQ3 2026
- Progress of Focal One system sales and installed base in the U.S. and EuropeQ3 2026
- Timing and terms of the exits from ESWL and Distribution2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Founded in 1979 as a French société anonyme and headquartered in Vaulx-en-Velin, the company focuses on HIFU technology, whose main commercial product is Focal One Robotic HIFU, used to ablate prostate tumour tissue in focal treatment 1. The business model combines equipment sales with recurring revenue from consumables, treatments (RPP and leases) and maintenance services for the installed base 1. In May 2026 management decided to exit the ESWL and Distribution segments, and the company announced a rename to FocalTherics with a focus solely on robotic focal therapy 23.
Expansion of clinical indications is central to the strategy: the company sponsors studies for benign prostatic hyperplasia (BPH) and holds a Breakthrough Device designation for deep infiltrating endometriosis, with a CE mark for rectal endometriosis from March 2025 1. A commercial endometriosis programme was launched in Europe in the second quarter of 2026 3.
Research and development rests on three pillars: imaging and targeting precision, automation and software intelligence (including AI algorithms in development), and expansion into new urologic and non-urologic indications 1. In November 2025 the system received FDA 510(k) clearance for the latest Focal One i evolution 1.
Segments
HIFU (Focal One)
The HIFU segment is the only continuing segment. Its revenue grew 44.8% in fiscal 2025 to 37.4 million USD 1, and total revenue in the first half of 2026 reached 24.8 million USD 2. Guidance for 2026 targets between 50.0 and 54.0 million USD 3.
ESWL and Distribution
The ESWL (lithotripsy) and Distribution segments are being exited and are reported as discontinued operations from the second quarter of 2026 23. Until the transactions, which could be completed within one year of the held-for-sale classification, their results are excluded from continuing revenue 2.
Market context
The addressable market is treatment of localized prostate cancer and, potentially, endometriosis and benign prostatic hyperplasia. The company reports an installed base of 184 Focal One systems at June 30, 2026, of which 96 are in the United States 3. The U.S. share of net sales rose to 40% in 2025 from 28% in 2024 1.
Demand for focal therapy could grow if clinical studies such as FARP and HIFI confirm non-inferiority to surgery over the long term 1. Commercial success, however, depends on reimbursement by health authorities and third-party payers, which is not assured 1.
Trends
- Adoption of focal therapy as an alternative to surgerytailwind
The FARP and HIFI studies suggest focal therapy could become a standard option for some patients with localized prostate cancer 1. If adoption grows, demand for Focal One could develop favourably.
- Expansion of clinical indicationstailwind
Programmes for BPH and endometriosis could widen the addressable market of the Focal One platform, if clinical results and regulatory approvals are confirmed 13.
- Tariff and trade policy pressureheadwind
Changes in U.S. trade policy, including tariffs, could affect the company's costs and margins, according to its declared risk factors 1.
- Reliance on financing and cyclical demandmixed
The company notes that its cash flow depends on cyclical product demand and that additional financing may be needed, which could constrain growth plans 1. The announced public offering is a step in that direction 3.
Competitive position
The reviewed sources do not name competitors, so competitive positioning is described only through the company's own technology and reported clinical advantages 1. The company states that HIFU could offer an advantage over surgery and radiotherapy, based on comparative study data 1.
Competitive risk is described as substantial: the company's products or services could become obsolete or uncompetitive 1. A rival technology could narrow the Focal One advantage in certain indications.
- Surgical treatment (robotic radical prostatectomy)
The standard alternative for prostate cancer; the FARP and HIFI studies compare focal results with prostatectomy 1.
- External beam radiotherapy (EBRT)
Compared with HIFU in a 10-year retrospective study cited by the company 1.
- Other makers of therapeutic ultrasound systems
The sources do not name rivals; the risk of new industry devices is mentioned in the risk factors 1.
- Developers of imaging and AI technology in urology
The company cites AI algorithm development as an advantage but also as a reputational risk 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report19 Aug 2026Other events · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report14 Aug 2026Material agreement · Financial statements and exhibits
- Current report13 Aug 2026Results of operations · Financial statements and exhibits
- Current report11 Aug 2026Results of operations · Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report26 Jun 2026Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report01 Jun 2026Regulation FD disclosure · Financial statements and exhibits
- Current report29 May 2026Other events
- Proxy statement14 May 2026
- Quarterly report07 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / FocalTherics™ (formerly EDAP TMS S.A.) · 25 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / FocalTherics™ (formerly EDAP TMS S.A.) · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / FocalTherics™ (formerly EDAP TMS S.A.) · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.